Browsing by Author "Nattika Saengkrit"

Filter results by typing the first few letters
Now showing 1 - 7 of 7
  • No Thumbnail Available
    PublicationMetadata only
    Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer
    (2020-12-01) Paweena Dana; Suphawadee Bunthot; Kunat Suktham; Suvimol Surassmo; Teerapong Yata; Katawut Namdee; Werayut Yingmema; Thunyatorn Yimsoo; Uracha Rungsardthong Ruktanonchai; Sith Sathornsumetee; Nattika Saengkrit; Chulalongkorn University; Thailand National Nanotechnology Center; Thammasat University; Faculty of Medicine, Siriraj Hospital, Mahidol University
    © 2020 Elsevier B.V. Cisplatin (Cis) is a widely used chemotherapeutic drug for cancer treatment. However, toxicities and drug resistance limit the use of cisplatin. This study was aimed to improve cisplatin delivery using a targeting strategy to reduce the toxicity. In the present study, combinations of poly lactic-co-glycolic acids (PLGA) and liposomes were used as carriers for cisplatin delivery. In addition, to target the nanoparticle towards tumor cells, the liposome was conjugated with Avastin®, an anti-VEGF antibody. Cisplatin was loaded into PLGA using the double emulsion solvent evaporation method and further encapsulated in an Avastin® conjugated liposome (define herein as L-PLGA-Cis-Avastin®). Their physicochemical properties, including particle size, ζ-potential, encapsulation efficiency and drug release profiles were characterized. In addition, a study of the efficiency of tumor targeted drug delivery was conducted with cervical tumor bearing mice via intravenous injection. The therapeutic effect was examined in a 3D spheroid of SiHa cell line and SiHa cells bearing mice. The L-PLGA-Cis-Avastin® prompted a significant effect on cell viability and triggered cytotoxicity of SiHa cells. A cell internalization study confirmed that the L-PLGA-Cis-Avastin® had greater binding specificity to SiHa cells than those of L-PLGA-Cis or free drug, resulting in enhanced cellular uptake. Tumor targeting specificity was finally confirmed in xenograft tumors. Taken together, this nanoparticle could serve as a promising specific targeted drug for cervical cancer treatment.
  • No Thumbnail Available
    PublicationMetadata only
    Chitosan and its quaternized derivative as effective long dsRNA carriers targeting shrimp virus in Spodoptera frugiperda 9 cells
    (2012-08-31) Gatesara Theerawanitchpan; Nattika Saengkrit; Warayuth Sajomsang; Pattarapond Gonil; Uracha Ruktanonchai; Somsak Saesoo; Timothy W. Flegel; Vanvimon Saksmerprome; Center of Excellence for Shrimp Molecular Biology and Biotechnology (Centex Shrimp); Mahidol University; Thailand National Science and Technology Development Agency; Thailand National Center for Genetic Engineering and Biotechnology
    RNA interference (RNAi) is a promising strategy to combat shrimp viral pathogens at lab-scale experiments. Development of effective orally delivered agents for double-stranded (ds)RNA is necessary for RNAi application at farm level. Since continuous shrimp cell lines have not been established, we are developing a dsRNA-delivery system in Spodoptera frugiperda (Sf9) cells for studying in vitro RNAi-mediated gene silencing of shrimp virus. Sf9 cells challenged with yellow head virus (YHV) were used for validating nanoparticles as effective dsRNA carriers. Inexpensive and biodegradable polymers, chitosan and its quarternized derivative (QCH4), were formulated with long dsRNA ( > 100bp) targeting YHV. Their morphology and physicochemical properties were examined. When treated with chitosan- and QCH4-dsRNA complexes, at least 50% reduction in YHV infection in Sf9 cells relative to the untreated control was evident at 24h post infection with low cytoxicity. Inhibitory effects of chitosan- and QCH4-dsRNA complexes were comparable to that of dsRNA formulated with Cellfectin ® , a commercial lipid-based transfection reagent. The natural and quaternized chitosan prepared in this study can be used for shrimp virus-specific dsRNA delivery in insect cultures, and have potential for future development of dsRNA carriers in shrimp feed. © 2012 Elsevier B.V.
  • No Thumbnail Available
    PublicationMetadata only
    Dry Formulations Enhanced Mucoadhesive Properties and Reduced Cold Chain Handing of Influenza Vaccines
    (2018-11-01) Nattika Saengkrit; Somsak Saesoo; Noppawan Woramongkolchai; Warayuth Sajomsang; Sarunya Phunpee; Tararaj Dharakul; Uracha Rungsardthong Ruktanonchai; Faculty of Medicine, Siriraj Hospital, Mahidol University; Thailand National Science and Technology Development Agency
    © 2018, American Association of Pharmaceutical Scientists. To alleviate concerns in health security, emergency flu vaccine stockpiles are required for ensuring rapid availability of vaccines when needed. Cold chain preservation, at high cost and risk, is necessary to maintain vaccine efficacy. This study aimed to develop a dry, easily storable formula for influenza vaccine preparation. The formulation with mucoadhesive properties is expected to facilitate rapid delivery via nasal administration. Chitosan, a cationic polymer, was used as cryo-protectant and to promote mucoadhesion. Optimal concentrations and molecular weights of chitosan polymers were screened, with short chain chitosan (10 kDa) being most suitable. H1N1 dry powder, in different formulations, was prepared via freeze-drying. A series of cryo-protectants, trehalose (T), chitosan (C), fetal bovine serum (FBS; F), or a combination of these (TCF), were screened for their effects on prolonging vaccine shelf life. Physicochemical monitoring (particle size and zeta potential) of powders complexed with mucin revealed that the order of cryo-protectant mixing during preparation was of critical importance. Results indicated that the TCF formula retains its activity up to 1 year as indicated by TCID 50 analysis. This approach was also successful at prolonging the shelf life of H3N2 vaccine, and has the potential for large-scale implementation, especially in developed countries where long-term storage of vaccines is problematic.
  • No Thumbnail Available
    PublicationMetadata only
    Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma
    (2021-08-01) Paweena Dana; Jakarwan Yostawonkul; Walailuk Chonniyom; Onuma Unger; Sakhiran Sakulwech; Sith Sathornsumetee; Nattika Saengkrit; Siriraj Hospital; Thailand National Nanotechnology Center
    Glioblastoma, GBM, is a primary malignant brain tumor and is one of the most difficult-to-treat cancers. The inability of drugs to cross the blood brain barrier (BBB) is the main obstacle for treating brain cancers. The development of drug delivery systems which improve the permeation across the BBB is the focus of this research, specifically the benefits and use of nanostructured lipid carriers (NLC). The anti-inflammatory and anti-tumor activity of garlic oil have been widely studied. However, direct treatment with garlic oil is restricted due to its low bioavailability and the application of drug for brain cancer to improve the efficiency of garlic oil, a NLC was developed as a carrier of garlic oil. The garlic NLC was formulated using the hot high-pressure homogenization technique. The physicochemical properties of the garlic NLC were analyzed using dynamic light scattering. Size of the garlic NLC was 136.8 ± 0.56 nm and the zeta potentials of each formulation were −36.27 ± 0.96 mV and PDI 0.163 ± 0.03. The effect of garlic NLC on the cell viability of the glioma cell was determined using a MTT assay. The garlic NLC had higher efficiency towards inhibiting cell viability of glioma cells compared to free garlic oil. In addition, the effects of the garlic NLC on cell migration and cell invasion were assessed using a Boyden chamber assay. The migration and invasion abilities of garlic NLC treated cells were significantly decreased compared to the control and free garlic oil. Moreover, in vitro BBB was used to test permeation of garlic oil across BBB. Interestingly, garlic NLC could cross the BBB while the free garlic oil could not. Taken together, garlic NLC might be applicable as an alternative therapeutic treatment strategy for brain cancer.
  • No Thumbnail Available
    PublicationMetadata only
    The PEI-introduced CS shell/PMMA core nanoparticle for silencing the expression of E6/E7 oncogenes in human cervical cells
    (2012-10-15) Nattika Saengkrit; Phakorn Sanitrum; Noppawan Woramongkolchai; Somsak Saesoo; Nuttaporn Pimpha; Saowaluk Chaleawlert-Umpon; Tewin Tencomnao; Satit Puttipipatkhachorn; Thailand National Science and Technology Development Agency; Chulalongkorn University; Mahidol University
    In this study, we examined the potential of cationic nanoparticle - polyethyleneimine-introduced chitosan shell/poly (methyl methacrylate) core nanoparticles (CS-PEI) for siRNA delivery. Initially, DNA delivery was performed to validate the capability of CS-PEI for gene delivery in the human cervical cancer cell line, SiHa. siRNA delivery were subsequently carried out to evaluate the silencing effect on targeted E6 and E7 oncogenes. Physicochemical properties including size, zeta potential and morphology of CS-PEI/DNA and CS-PEI/siRNA complexes, were analyzed. The surface charges and sizes of the complexes were observed at different N/P ratios. The hydrodynamic sizes of the CS-PEI/DNA and CS-PEI/siRNA were approximately 300-400 and 400-500 nm, respectively. Complexes were positively charged depending on the amount of added CS-PEI. AFM images revealed the mono-dispersed and spherical shapes of the complexes. Gel retardation assay confirmed that CS-PEI nanoparticles completely formed complexes with DNA and siRNA at a N/P ratio of 1.6. For DNA transfection, CS-PEI provided the highest transfection result. Localization of siRNA delivered through CS-PEI was confirmed by differential interference contrast (DIC) confocal imaging. The silencing effect of siRNA specific to HPV 16 E6/E7 oncogene was examined at 18 and 24 h post-transfection. The results demonstrated the capacity of CS-PEI to suppress the expression of HVP oncogenes. © 2012 Elsevier Ltd.
  • No Thumbnail Available
    PublicationMetadata only
    Surface modification of PLGA nanoparticles by carbopol to enhance mucoadhesion and cell internalization
    (2015-06-01) Suvimol Surassmo; Nattika Saengkrit; Uracha Rungsardthong Ruktanonchai; Kunat Suktham; Noppawan Woramongkolchai; Tuksadon Wutikhun; Satit Puttipipatkhachorn; Thailand National Science and Technology Development Agency; Mahidol University
    © 2015 Elsevier B.V. Mucoadhesive poly (lactic-co-glycolic acid) (PLGA) nanoparticles having a modified shell-matrix derived from polyvinyl alcohol (PVA) and Carbopol (CP), a biodegradable polymer coating, to improve the adhesion and cell transfection properties were developed. The optimum formulations utilized a CP concentration in the range of 0.05-0.2%. w/v, and were formed using modified emulsion-solvent evaporation technique. The resulting CP-PLGA nanoparticles were characterized in terms of their physical and chemical properties. The absorbed CP on the PLGA shell-matrix was found to affect the particle size and surface charge, with 0.05% CP giving rise to smooth spherical particles (0.05CP-PLGA) with the smallest size (285.90. nm), and strong negative surface charge (-25.70. mV). The introduction of CP results in an enhancement of the mucoadhesion between CP-PLGA nanoparticles and mucin particles. In vitro cell internalization studies highlighted the potential of 0.05CP-PLGA nanoparticles for transfection into SiHa cells, with uptake being time dependent. Additionally, cytotoxicity studies of CP-PLGA nanoparticles against SiHa cancer cells indicated that low concentrations of the nanoparticles were non-toxic to cells (cell viability >80%). From the various formulations studied, 0.05CP-PLGA nanoparticles proved to be the optimum model carrier having the required mucoadhesive profile and could be an alternative therapeutic efficacy carrier for targeted mucosal drug delivery systems with biodegradable polymer.
  • No Thumbnail Available
    PublicationMetadata only
    Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract
    (2018-09-07) Katawut Namdee; Mattaka Khongkow; Suwimon Boonrungsiman; Naiyaphat Nittayasut; Paladd Asavarut; Sasithon Temisak; Nattika Saengkrit; Satit Puttipipatkhachorn; Amin Hajitou; Kiat Ruxrungtham; Teerapong Yata; Chulalongkorn University; Imperial College London; Mahidol University; Thailand National Science and Technology Development Agency; National Institute of Metrology (Thailand) (NIMT)
    © 2018 The Author(s) The use of the gastrointestinal tract as a site for the local delivery of DNA is an exciting prospect. In order to obtain an effective vector capable of delivering a gene of interest to target cells to achieve sufficient and sustained transgene expression, with minimal toxicity, we developed a new generation of filamentous bacteriophage. This particular bacteriophage was genetically engineered to display an arginine-glycine-aspartic acid (RGD) motif (an integrin-binding peptide) on the major coat protein pVIII and carry a mammalian DNA cassette. One unanticipated observation is the thermoresponsive behavior of engineered bacteriophage. This finding has led us to simplify the isolation method to purify bacteriophage particles from cell culture supernatant by low-temperature precipitation. Our results showed that, in contrast to non-surface modified, the RGD-modified bacteriophage was successfully used to deliver a transgene to mammalian cells. Our in vitro model of the human intestinal follicle-associated epithelium also demonstrated that bacteriophage particles were stable in simulated gastrointestinal fluids and able to cross the human intestinal barrier. In addition, we confirmed an adjuvant property of the engineered bacteriophage to induce nitric oxide production by macrophages. In conclusion, our study demonstrated the possibility of using bacteriophage for gene transfer in the gastrointestinal tract.